$ERNA
Eterna Therapeutics Inc. Stock $erna

$erna Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000114036123039283 Filed on August 11, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$51.00K	$0.00	$0.00
YoY Change
Cost Of Revenue	$120.0K	$0.00
YoY Change
Gross Profit	-$69.00K	$0.00
YoY Change
Gross Profit Margin	-135.29%
Selling, General & Admin	$3.980M	$2.510M	$5.433M
YoY Change	19.16%	-53.8%	18.6%
% of Gross Profit
Research & Development	$1.457M	$1.579M	$1.685M
YoY Change	-70.64%	-6.29%	-68.98%
% of Gross Profit
Depreciation & Amortization	$20.00K	$20.00K	$68.00K
YoY Change	-50.0%	-70.59%	78.01%
% of Gross Profit
Operating Expenses	$5.436M	$4.549M	$13.88M
YoY Change	-34.54%	-67.23%	38.62%
Operating Profit	-$5.505M	-$4.549M	-$13.88M
YoY Change	-33.71%	-67.23%	38.62%
Interest Expense	-$110.0K	$20.00K	-$296.0K
YoY Change	450.0%	-106.76%
% of Operating Profit
Other Income/Expense, Net	-$94.00K	$45.00K	$10.48M
YoY Change	-109.47%	-99.57%	-14658.33%
Pretax Income	-$5.599M	-$4.504M	-$3.398M
YoY Change	-23.42%	32.55%	-66.31%
Income Tax	-$8.000K	$4.000K	$0.00
% Of Pretax Income
Net Earnings	-$5.600M	-$4.508M	-$3.400M
YoY Change	-23.29%	32.59%	-66.29%
Net Earnings / Revenue	-10980.39%
Basic Earnings Per Share	-$1.03	-$0.85	-$0.06
Diluted Earnings Per Share	-$1.03	-$0.85	-$0.06
COMMON SHARES
Basic Shares Outstanding	5.410M	5.270M	58.81M
Diluted Shares Outstanding	5.410M	5.303M	58.81M

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.550M	$1.840M	$19.41M
YoY Change	-65.66%	-90.52%	-61.31%
Cash & Equivalents	$4.551M	$1.837M	$19.41M
Short-Term Investments
Other Short-Term Assets	$700.0K	$1.070M	$1.824M
YoY Change	-58.08%	-41.34%	4.04%
Inventory
Prepaid Expenses
Receivables	$1.780M	$980.0K
Other Receivables	$1.776M	$984.0K	$694.0K
Total Short-Term Assets	$7.031M	$3.891M	$21.93M
YoY Change	-55.65%	-82.25%	-57.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$173.0K	$193.0K	$424.0K
YoY Change	-25.11%	-54.48%	-27.15%
Goodwill	$2.000M	$2.000M	$2.000M
YoY Change	0.0%	0.0%	-2.14%
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00	$89.00K
YoY Change	-100.0%	-100.0%	-82.71%
Other Assets	$4.045M	$1.374M
YoY Change	393.89%
Total Long-Term Assets	$45.22M	$43.06M	$4.977M
YoY Change	791.15%	765.24%	-61.02%
TOTAL ASSETS
Total Short-Term Assets	$7.031M	$3.891M	$21.93M
Total Long-Term Assets	$45.22M	$43.06M	$4.977M
Total Assets	$52.25M	$46.95M	$26.90M
YoY Change	149.68%	74.54%	-58.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.464M	$2.675M	$1.478M
YoY Change	27.3%	80.99%	-59.83%
Accrued Expenses	$5.019M	$2.109M	$3.821M
YoY Change	55.39%	-44.81%	99.41%
Deferred Revenue
YoY Change
Short-Term Debt	$1.640M	$1.750M	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.626M	$7.165M	$7.118M
YoY Change	28.91%	0.66%	-7.37%
LONG-TERM LIABILITIES
Long-Term Debt	$3.450M	$330.0K	$0.00
YoY Change	34400.0%
Other Long-Term Liabilities	$35.61M	$35.59M	$48.00K
YoY Change	2007.1%	74045.83%	109.95%
Total Long-Term Liabilities	$39.06M	$35.92M	$48.00K
YoY Change	2211.24%	74733.33%	109.95%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.626M	$7.165M	$7.118M
Total Long-Term Liabilities	$39.06M	$35.92M	$48.00K
Total Liabilities	$48.69M	$43.09M	$12.12M
YoY Change	301.93%	255.42%	-58.94%
SHAREHOLDERS EQUITY
Retained Earnings	-$180.8M	-$175.2M	-$153.5M
YoY Change	12.44%	14.14%	135.52%
Common Stock	$27.00K	$27.00K	$287.0K
YoY Change	80.0%	-90.59%	28.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.562M	$3.866M	$14.78M
YoY Change
Total Liabilities & Shareholders Equity	$52.25M	$46.95M	$26.90M
YoY Change	149.68%	74.54%	-58.43%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$5.600M	-$4.508M	-$3.400M
YoY Change	-23.29%	32.59%	-66.29%
Depreciation, Depletion And Amortization	$20.00K	$20.00K	$68.00K
YoY Change	-50.0%	-70.59%	78.01%
Cash From Operating Activities	-$5.830M	-$3.870M	-$3.993M
YoY Change	-4.58%	-3.08%	-41.32%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$187.0K
YoY Change	-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$100.0K
YoY Change		-100.0%	-21839.13%
Cash From Investing Activities	$0.00	$0.00	-$87.00K
YoY Change	-100.0%	-100.0%	18813.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	8.540M	310.0K	-13.00K
YoY Change	85300.0%	-2484.62%	-100.03%
NET CHANGE
Cash From Operating Activities	-5.830M	-3.870M	-3.993M
Cash From Investing Activities	0.000	0.000	-87.00K
Cash From Financing Activities	8.540M	310.0K	-13.00K
Net Change In Cash	2.710M	-3.560M	-4.093M
YoY Change	-144.07%	-13.02%	-109.8%
FREE CASH FLOW
Cash From Operating Activities	-$5.830M	-$3.870M	-$3.993M
Capital Expenditures	$0.00	$0.00	-$187.0K
Free Cash Flow	-$5.830M	-$3.870M	-$3.806M
YoY Change	-5.36%	1.68%	-44.07%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	erna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-215000
CY2023Q2	us-gaap	Cash Cash	1837000
CY2022Q4	us-gaap	Cash Cash	11446000
CY2023Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	984000
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	951000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1284000
CY2023Q2	us-gaap	Assets Current AssetsCurrent	3891000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	13681000
CY2023Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4095000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4095000
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	193000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	236000
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	35357000
CY2023Q2	us-gaap	Goodwill Goodwill	2044000
CY2022Q4	us-gaap	Goodwill Goodwill	2044000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	156000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	156000
CY2023Q2	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	156000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.005
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.005
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	27000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	26000
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	179067000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	177377000
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-175229000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-165297000
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	3866000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	12107000
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	46954000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22279000
	us-gaap	Net Income Loss NetIncomeLoss	-12773000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	42000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	104000
	us-gaap	Share Based Compensation ShareBasedCompensation	903000
	us-gaap	Share Based Compensation ShareBasedCompensation	2062000
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	83000
	erna	Gain Loss On Disposal Of Fixed Assets GainLossOnDisposalOfFixedAssets	1000
	erna	Gain Loss On Disposal Of Fixed Assets GainLossOnDisposalOfFixedAssets	274000
	erna	Gain On Termination Of Lease GainOnTerminationOfLease	0
	erna	Gain On Termination Of Lease GainOnTerminationOfLease	85000
	erna	Loss On Non Controlling Investment LossOnNonControllingInvestment	59000
	erna	Loss On Non Controlling Investment LossOnNonControllingInvestment	911000
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	33000
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	5000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-214000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	727000
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	481000
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-11000
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	0
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	250000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	80000
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1183000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9921000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9425000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	233000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-133000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	312000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11980000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-9609000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	2422000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15541000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16985000
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5932000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19407000
	us-gaap	Interest Paid Net InterestPaidNet	13000
	us-gaap	Interest Paid Net InterestPaidNet	14000
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4000
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	8000
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1837000
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19407000
CY2023Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	4095000
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	0
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5932000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19407000
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-4500000
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	4100000
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0000748592
	erna	License Agreement Automatic Renewal Term LicenseAgreementAutomaticRenewalTerm	P2Y6M
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1070000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1030000
CY2023Q2	us-gaap	Equity Method Investments EquityMethodInvestments	0
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	59000
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1374000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1134000
CY2023Q2	us-gaap	Assets Assets	46954000
CY2022Q4	us-gaap	Assets Assets	22279000
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2675000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1620000
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2109000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3626000
CY2023Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	8000
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	0
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	173000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	295000
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	7165000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7654000
CY2023Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	185000
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	331000
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	34963000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	887000
CY2023Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	250000
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0
CY2023Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	107000
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0
CY2023Q2	us-gaap	Liabilities Liabilities	43088000
CY2022Q4	us-gaap	Liabilities Liabilities	10172000
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.005
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.005
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	156000
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	156000
CY2022Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	156000
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5410000
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5410000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5127000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5127000
CY2023Q2	erna	License Costs LicenseCosts	0
CY2022Q2	erna	License Costs LicenseCosts	0
	erna	License Costs LicenseCosts	50000
	erna	License Costs LicenseCosts	0
CY2023Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1579000
CY2022Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1685000
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3253000
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3467000
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2510000
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6205000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6102000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10719000
CY2023Q2	erna	Research And Development In Process Asset Acquisition ResearchAndDevelopmentInProcessAssetAcquisition	460000
CY2022Q2	erna	Research And Development In Process Asset Acquisition ResearchAndDevelopmentInProcessAssetAcquisition	0
	erna	Research And Development In Process Asset Acquisition ResearchAndDevelopmentInProcessAssetAcquisition	460000
	erna	Research And Development In Process Asset Acquisition ResearchAndDevelopmentInProcessAssetAcquisition	0
CY2023Q2	us-gaap	Impairment Of Ongoing Project ImpairmentOfOngoingProject	0
CY2022Q2	us-gaap	Impairment Of Ongoing Project ImpairmentOfOngoingProject	5990000
	us-gaap	Impairment Of Ongoing Project ImpairmentOfOngoingProject	0
	us-gaap	Impairment Of Ongoing Project ImpairmentOfOngoingProject	5990000
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	4549000
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.85
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.85
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	13880000
	us-gaap	Operating Expenses OperatingExpenses	9865000
	us-gaap	Operating Expenses OperatingExpenses	20176000
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4549000
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-13880000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9865000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-20176000
CY2023Q2	erna	Warrant Liabilities Expense WarrantLiabilitiesExpense	-191000
CY2022Q2	erna	Warrant Liabilities Expense WarrantLiabilitiesExpense	-10792000
	erna	Warrant Liabilities Expense WarrantLiabilitiesExpense	-146000
	erna	Warrant Liabilities Expense WarrantLiabilitiesExpense	-9470000
CY2023Q2	erna	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	118000
CY2022Q2	erna	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	0
	erna	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	118000
	erna	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	0
CY2023Q2	erna	Loss On Non Controlling Investment LossOnNonControllingInvestment	8000
CY2022Q2	erna	Loss On Non Controlling Investment LossOnNonControllingInvestment	296000
	erna	Loss On Non Controlling Investment LossOnNonControllingInvestment	59000
	erna	Loss On Non Controlling Investment LossOnNonControllingInvestment	911000
CY2023Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	256000
CY2022Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	14000
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	255000
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	1156000
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	45000
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	10482000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-50000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7403000
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4504000
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3398000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9915000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12773000
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-4508000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-3398000
	us-gaap	Net Income Loss NetIncomeLoss	-9924000
	us-gaap	Net Income Loss NetIncomeLoss	-12773000
CY2023Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	8000
CY2022Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	8000
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	8000
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	8000
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4516000
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3406000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9932000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12781000
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.16
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.16
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.9
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.9
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.55
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.55
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5303000
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5303000
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2940000
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2940000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5215000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5215000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2811000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2811000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	7380000
CY2023Q2	erna	Stock Issued During Period Value Acquisitions2 StockIssuedDuringPeriodValueAcquisitions2	208000
CY2023Q2	erna	Stock Issued During Period Value Stock Purchase Agreement StockIssuedDuringPeriodValueStockPurchaseAgreement	580000
CY2023Q2	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	8000
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	214000
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-4508000
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	3866000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	12107000
	erna	Stock Issued During Period Value Acquisitions2 StockIssuedDuringPeriodValueAcquisitions2	208000
	erna	Stock Issued During Period Value Stock Purchase Agreement StockIssuedDuringPeriodValueStockPurchaseAgreement	580000
	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	8000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	903000
	us-gaap	Net Income Loss NetIncomeLoss	-9924000
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	3866000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	17311000
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-5000
CY2022Q2	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	8000
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	879000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-3398000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	14779000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	25503000
	erna	Stock Issued During Period Value Private Offering StockIssuedDuringPeriodValuePrivateOffering	0
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-5000
	erna	Stock Issued During Period Value Forfeiture Of Unvested Restricted Stock StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock	0
	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	8000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2062000
	us-gaap	Net Income Loss NetIncomeLoss	-12773000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	14779000
	us-gaap	Net Income Loss NetIncomeLoss	-9924000
	erna	Commitment Shares Issue Expense CommitmentSharesIssueExpense	249000
	erna	Commitment Shares Issue Expense CommitmentSharesIssueExpense	0
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	-11000
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	0
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	186000
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	772000
	erna	Non Cash Research And Development In Process Asset Acquisition NonCashResearchAndDevelopmentInProcessAssetAcquisition	433000
	erna	Non Cash Research And Development In Process Asset Acquisition NonCashResearchAndDevelopmentInProcessAssetAcquisition	0
	us-gaap	Impairment Of Ongoing Project ImpairmentOfOngoingProject	0
	us-gaap	Impairment Of Ongoing Project ImpairmentOfOngoingProject	5990000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-146000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-9470000
	erna	Gain Loss On Change In Fair Value Of Contingent Consideration GainLossOnChangeInFairValueOfContingentConsideration	-118000
	erna	Gain Loss On Change In Fair Value Of Contingent Consideration GainLossOnChangeInFairValueOfContingentConsideration	0
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-454000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2295000
	erna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-153000
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-875000
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	100000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11993000
	erna	Proceeds From Issuance Of Common Stock Pursuant To Stock Purchase Agreement ProceedsFromIssuanceOfCommonStockPursuantToStockPurchaseAgreement	320000
	erna	Proceeds From Issuance Of Common Stock Pursuant To Stock Purchase Agreement ProceedsFromIssuanceOfCommonStockPursuantToStockPurchaseAgreement	0
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	5000
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	8000
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	8000
	erna	Contingent Consideration For Asset Acquisition ContingentConsiderationForAssetAcquisition	225000
	erna	Contingent Consideration For Asset Acquisition ContingentConsiderationForAssetAcquisition	0
	erna	Issuance Of Common Stock For Asset Acquisition IssuanceOfCommonStockForAssetAcquisition	208000
	erna	Issuance Of Common Stock For Asset Acquisition IssuanceOfCommonStockForAssetAcquisition	0
	erna	Initial Measurement Of Right Of Use Assets InitialMeasurementOfRightOfUseAssets	34410000
	erna	Initial Measurement Of Right Of Use Assets InitialMeasurementOfRightOfUseAssets	1706000
	erna	Initial Measurement Of Lease Liabilities InitialMeasurementOfLeaseLiabilities	34169000
	erna	Initial Measurement Of Lease Liabilities InitialMeasurementOfLeaseLiabilities	1706000
CY2023Q2	erna	Number Of In Licensed Portfolio Patents NumberOfInLicensedPortfolioPatents	100
CY2023Q2	us-gaap	Cash Cash	1800000
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-175200000
	us-gaap	Net Income Loss NetIncomeLoss	-9900000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9900000
CY2022Q4	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	45500
CY2022Q4	us-gaap	Line Of Credit LineOfCredit	4100000
CY2023Q2	erna	Allocated Percentage Of Fair Value Consideration To Purchased License AllocatedPercentageOfFairValueConsiderationToPurchasedLicense	1
CY2023Q1	erna	Proceeds From Option And License Agreement ProceedsFromOptionAndLicenseAgreement	250000
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	1
CY2023Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	250000
CY2023Q2	erna	Option Fee Obligation Payment Percentage OptionFeeObligationPaymentPercentage	0.20
	erna	License Costs LicenseCosts	50000
CY2023Q2	erna	License Costs LicenseCosts	0
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	800000
CY2022Q2	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	800000
CY2023Q2	erna	Lease Liability Incremental Amount Above Tenant Improvement Allowance LeaseLiabilityIncrementalAmountAboveTenantImprovementAllowance	600000
CY2023Q2	erna	Other Receivable For Reimbursement Under Tenant Improvement Allowance OtherReceivableForReimbursementUnderTenantImprovementAllowance	300000
CY2023Q2	erna	Sublease Tenant Improvement Allowance Paid But Not Submitted For Reimbursement SubleaseTenantImprovementAllowancePaidButNotSubmittedForReimbursement	700000
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	67000
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	146000
	us-gaap	Operating Lease Cost OperatingLeaseCost	135000
	us-gaap	Operating Lease Cost OperatingLeaseCost	333000
CY2023Q2	us-gaap	Sublease Income SubleaseIncome	21000
CY2022Q2	us-gaap	Sublease Income SubleaseIncome	21000
	us-gaap	Sublease Income SubleaseIncome	42000
	us-gaap	Sublease Income SubleaseIncome	42000
CY2023Q2	us-gaap	Variable Lease Cost VariableLeaseCost	7000
CY2022Q2	us-gaap	Variable Lease Cost VariableLeaseCost	51000
	us-gaap	Variable Lease Cost VariableLeaseCost	12000
	us-gaap	Variable Lease Cost VariableLeaseCost	53000
CY2023Q2	us-gaap	Lease Cost LeaseCost	53000
CY2022Q2	us-gaap	Lease Cost LeaseCost	176000
	us-gaap	Lease Cost LeaseCost	105000
	us-gaap	Lease Cost LeaseCost	344000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1030000
	erna	Initial Measurement Of Operating Lease Rou Assets InitialMeasurementOfOperatingLeaseROUAssets	34410000
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	83000
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	35357000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1182000
	erna	Initial Measurement Of Operating Lease Liabilities InitialMeasurementOfOperatingLeaseLiabilities	34169000
	erna	Principal Payments On Operating Lease Liabilities PrincipalPaymentsOnOperatingLeaseLiabilities	215000
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	35136000
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	34963000
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	173000
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y3M18D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.126
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1064000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	5931000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6065000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6227000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	6298000
CY2023Q2	erna	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	40224000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	65809000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	30673000
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	35136000
CY2023Q2	us-gaap	Goodwill Goodwill	2000000
CY2023Q1	us-gaap	Share Price SharePrice	3.4
CY2023Q2	us-gaap	Share Price SharePrice	2.26
CY2023Q1	erna	Percentage Of Sublicense Fees Paid Before License Expiration Date PercentageOfSublicenseFeesPaidBeforeLicenseExpirationDate	0.20
CY2023Q1	erna	Percentage Of Sublience Fees Received During Renewal Term PercentageOfSublienceFeesReceivedDuringRenewalTerm	0.30
	erna	Notice Period For First Termination Of Contract NoticePeriodForFirstTerminationOfContract	P120D
CY2023Q1	erna	Percentage Of Sublience Fees Received During Renewal Term PercentageOfSublienceFeesReceivedDuringRenewalTerm	0.30
CY2023Q2	erna	Legal Fees And Settlements LegalFeesAndSettlements	349000
CY2023Q1	erna	Legal Fees And Settlements LegalFeesAndSettlements	1138000
CY2023Q2	erna	Accrued Clinical Current AccruedClinicalCurrent	310000
CY2023Q1	erna	Accrued Clinical Current AccruedClinicalCurrent	570000
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	431000
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	333000
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	324000
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1065000
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	695000
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	520000
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2109000
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3626000
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	214000
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	879000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	903000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2062000
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4713
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5243000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5243000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	563000
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	563000

Files In Submission

Name	View Source	Status
0001140361-23-039283-index-headers.html	Edgar Link	pending
0001140361-23-039283-index.html	Edgar Link	pending
0001140361-23-039283.txt	Edgar Link	pending
0001140361-23-039283-xbrl.zip	Edgar Link	pending
brhc20057085_10q.htm	Edgar Link	pending
brhc20057085_ex31-1.htm	Edgar Link	pending
brhc20057085_ex31-2.htm	Edgar Link	pending
brhc20057085_ex32-1.htm	Edgar Link	pending
brhc20057085_ex32-2.htm	Edgar Link	pending
erna-20230630.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image00007.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
erna-20230630_cal.xml	Edgar Link	unprocessable
erna-20230630_def.xml	Edgar Link	unprocessable
erna-20230630_lab.xml	Edgar Link	unprocessable
erna-20230630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
brhc20057085_10q_htm.xml	Edgar Link	completed
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ERNA
Eterna Therapeutics Inc. Stock $erna

2023 Q3 Form 10-Q Financial Statement

#000114036123039283 Filed on August 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ERNA Eterna Therapeutics Inc. Stock $erna

2023 Q3 Form 10-Q Financial Statement

#000114036123039283 Filed on August 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ERNA
Eterna Therapeutics Inc. Stock $erna